DOC

[This is a document template that you can use to ensure

By Michele Bennett,2014-02-27 06:43
7 views 0
[This is a document template that you can use to ensure

[This is a document template that you can use to ensure that your paper can be read and typeset with

    ease:

    ; Heading levels and text layout have been prepared for you.

    ; The red text explains each element.

    ; You will need to delete the red text and/or replace the text with required details prior to submitting

    your paper.

    ; For typesetting it is preferable if you prepare your manuscript using Styles, eg. Heading 1, Normal,

    etc.]

REVIEW [This is the type of paper: Please see http://www.dovepress.com/core-evidence-journal for

    examples.]

    Short running header [This is a summary of the manuscript title and should only be six to ten words]

    [First author] et al

    Drug name: Evidence supporting its therapeutic use in

    [complete title with drug name and name of therapy]

    1Author name [Please list all authors here and do not include abbreviated qualifications]

    2Author name

1Author affiliations [list all author affiliations in the form of department, institution, city, state, country];

    2Author affiliations

Correspondence: [Full name of corresponding author.]

    [Include full postal address here.]

    Tel [Full international phone number, eg, +1 404 234 5433]

    Fax [Full international fax number.]

    Email

     1

    [Abstract: There are two types of abstract. One is structured and the other is not. Core Evidence uses a structured abstract. This should be no more than 300 words and follow the structure as outlined below.

    Please see http://www.dovepress.com/core-evidence-journal for examples.] Introduction:

    Aims:

    Evidence review:

    Place in therapy:

    Conclusion:

    Keywords: [Choose four to six keywords. They should not repeat words given in the title.]

Core Evidence clinical impact summary for [Insert drug name/therapy here.]

    Outcome measure Evidence Implications

    Disease-oriented evidence

Patient-oriented evidence

Economic evidence

Abbreviations:

    [Generally each major section of your manuscript should have a heading. The most common breakdown

    of a paper is given below, with some subheadings related to the above example text. Please delete or

    1,25include as needed. Please note that citations are in superscript numerals following the punctuation. Abbreviations are defined in full at their first instance.]

     2

    Scope, aims, and objectives

Mechanism of action

    Drug formulation and dosing

Pharmacokinetics

Clinical efficacy

Etonogestrel implant [This is an example of a level 2 heading.]

    Efficacy [This is an example of a level 3 heading.]

Tolerability

     3

Clinical indications

    Potential therapeutic indications for [Please complete with name of drug.]

Methods

Conclusion

Acknowledgments

Author contributions

    [Should you choose to add author contributions, please ensure that all authors meet the criteria listed on

    the Author Guidelines page of our website http://www.dovepress.com/author_guidelines.php?content_id=371].

     4

Disclosure

    The author reports no conflicts of interest in this work. [Each manuscript needs include a disclosure of

    financial interest or other conflict of interest statement. This is where these statements go].

References

    [The following are examples of our reference style. Please see

    http://www.dovepress.com/author_guidelines.php?folder_id=208 for more details.]

    1. Burnier M, Fricker AF, Hayoz D, et al. Pharmacokinetic and pharmacodynamic effects of YM087,

    a combined V1/V2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol.

    1999;55:633637.

    2. Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone

    by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med.

    2001;110:582584.

    3. Fried LF, Palevsky PM. Hyponatremia and hypernatremia. Med Clin North Am. 1997;81:585609.

    4. Gheorghiade M, Konstam MA, Burnett JC Jr, et al; Efficacy of Vasopressin Antagonism in Heart

    Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short term clinical effects of

    tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST

    Clinical Status Trials. JAMA. 2007;297:13321343.

    5. Vaprisol (conivaptan HCl injection) [package insert]. Deerfield IL: Astellas Tokai Co.; February

    2006.

     5

Table 1 [Table titles are in sentence case and do not end with a full-stop.]

Notes:

    Abbreviations: AUC, area under the curve; LS, least squares; NE, not estimable. [These are examples

    of format.]

     6

    Figure 1 [Title of figure is in sentence case and ends in a full stop. Please see http://www.dovepress.com/author_guidelines.php for our Figure requirements.]

    [Insert figure here if it is small enough. If large (1MB or more) please send in a separate Word document/PDF/.tiff/.jpg file.]

     7

Report this document

For any questions or suggestions please email
cust-service@docsford.com